Rare Disease · United Kingdom · In-Market

UK PNH Payer & HTA

Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000) at the ordinary £20,000–£30,000/QALY bar — the real payer question is how fast NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal.

Both drugs: standard TA route, same QALY barNHS HSS spend ~£60–90M/year~95% of NHS patients switched to ravulizumabUpdated Q3 2026
Commission This Assessment View Sample Assessment
Market United States GCC (Gulf) United Kingdom Germany France Stage
The Landscape

Ravulizumab and iptacopan both cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY bar; the live access question is how fast NHS converts patients onto oral iptacopan.

Ravulizumab (Ultomiris, AstraZeneca) and predecessor eculizumab were appraised via NICE's standard Technology Appraisal route, the same ordinary pathway used for most branded medicines, at the standard £20,000–£30,000 per QALY threshold. NICE TA698 (19 May 2021) recommended ravulizumab, contingent on a commercial arrangement, for patients with high disease activity or stable disease after at least six months on eculizumab; NHS England Highly Specialised Services now commissions it through 15 designated centres, and a completed switch programme moved an estimated 95% of NHS PNH patients from eculizumab to ravulizumab by 2023. Estimated NHS HSS spend on PNH complement inhibitors runs to £60–90 million a year across roughly 600 patients at post-arrangement net pricing.

Iptacopan (Fabhalta, Novartis) cleared the identical standard Technology Appraisal route: NICE TA1000 (4 September 2024, NICE's 1,000th published appraisal) recommends iptacopan, within its marketing authorisation, for adults with PNH and haemolytic anaemia (a broad population, with no restriction to patients intolerant of IV anti-C5 therapy), contingent on a commercial arrangement. With cost-effectiveness settled at the standard £20,000–£30,000/QALY threshold and a commercial arrangement already agreed, the constraint on iptacopan's UK uptake is no longer appraisal risk but the pace at which NHS complement-inhibitor patients are offered the oral switch from IV ravulizumab, and the commercial-arrangement economics AstraZeneca can defend against an already-entrenched net price.

TA698 & TA1000
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY threshold
£60–90M
Estimated annual NHS England Highly Specialised Services spend on PNH complement inhibitors across ~600 patients
TA1000
NICE's 1,000th technology appraisal (4 Sept 2024), recommending iptacopan for the full adult PNH-with-haemolytic-anaemia population, not just IV-intolerant patients
PAYER LANDSCAPE

UK PNH agent NICE and NHS status

Drug (Brand / INN)NICE HTA RouteNICE Recommendation & PASNHS Commissioning ChannelCost-Effectiveness PositionKey Payer Risk
Ultomiris (ravulizumab)Standard Technology Appraisal (TA698, 19 May 2021)Recommended with commercial arrangementNHS England HSS — 15 designated centresWithin standard £20K–£30K/QALY threshold post-arrangementIptacopan oral switching, not a negotiated reset, is the pricing risk
Fabhalta (iptacopan)Standard Technology Appraisal (TA1000, 4 Sept 2024)Recommended with commercial arrangementNHS England/Wales — mandatory funding liveWithin standard £20K–£30K/QALY threshold post-arrangementRecommended for the full adult PNH-with-haemolytic-anaemia population; no IV-intolerance restriction

Sources: NICE TA698 Final Appraisal Determination (ravulizumab), 19 May 2021; NICE TA1000 Final Appraisal Determination (iptacopan), 4 September 2024; NHS England Highly Specialised Services PNH commissioning data, 2023.

Commercial Questions

What this assessment answers

Every section answers a named commercial question your team is asking, scoped to your asset.

01
Now that both ravulizumab and iptacopan have cleared NICE's standard Technology Appraisal route at the same £20,000–£30,000/QALY bar, what commercial-arrangement terms did each secure, and what does that mean for iptacopan's realistic UK net price?

Delivers

  • TA698 and TA1000 recommendation terms and commercial-arrangement structure for each drug
  • standard £20,000–£30,000/QALY threshold benchmarking
  • net-price positioning implications for iptacopan against ravulizumab's entrenched NHS price
02
What is the current NHS England Highly Specialised Services commissioning pathway for PNH complement inhibitors, and how has the eculizumab-to-ravulizumab switch programme changed the patient base?

Delivers

  • 15-designated-centre HSS commissioning architecture
  • switch programme outcomes (~95% of NHS PNH patients now on ravulizumab)
  • NHS annual spend estimate (£60–90M) and per-patient net cost modelling
03
With iptacopan already NICE-recommended (TA1000) for the full PNH-with-haemolytic-anaemia population, how quickly will NHS HSS centres offer the oral switch to patients currently stable on IV ravulizumab?

Delivers

  • TA1000 mandatory NHS funding timeline
  • centre-level readiness for oral complement-inhibitor switching
  • commercial-arrangement economics shaping AstraZeneca's and Novartis's competing net-price positions

Custom assessment delivered in 72 hours.

Commission This Assessment
Contents

What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

1 UK PNH Payer & Commissioning Landscape — NHS England HSS Overview 4 pp
  • [object Object]
  • [object Object]
2 NICE Standard Technology Appraisal Route — TA698 and TA1000 Compared 6 pp
  • [object Object]
  • [object Object]
3 NHS PNH Commissioning Cost & the Eculizumab-to-Ravulizumab Switch 5 pp
  • [object Object]
  • [object Object]
4 Iptacopan NICE TA1000 — Commercial Arrangement & NHS Conversion Timeline 5 pp
  • [object Object]
  • [object Object]
5 NHS HSS Centre Network — Access Pathway & Oral Conversion Readiness 3 pp
  • [object Object]
  • [object Object]
6 Devolved Nations — Scotland (SMC) and Wales (AWMSG) Divergence Risk 3 pp
  • [object Object]
  • [object Object]
Appendix and source ledger included · 45-minute analyst readout included with delivery
Formats

Included with every brief

PDF
PDF Brief
PNH Payer & HTA Assessment — UK Complete Edition
25–30 page payer brief: NICE's standard Technology Appraisal route for both ravulizumab and iptacopan, NHS England HSS commissioning, the eculizumab-to-ravulizumab switch, and the oral-conversion opportunity.
XLS
Excel Model
Payer Coverage Grid — Excel
Drug-by-drug NICE HTA route, PAS status, NHS commissioning channel, and cost-effectiveness position for UK PNH agents in editable Excel format.
PPT
PowerPoint
Executive Readout — PowerPoint
12–15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.
Methodology

How AXLRx builds this assessment

Prepared by MoatRx analysts.

This assessment is built from NICE's published Technology Appraisal documentation, NHS England Highly Specialised Services commissioning specifications, and payer-facing evidence submissions for ravulizumab and iptacopan in PNH.

Key sources: NICE TA698 Final Appraisal Determination (ravulizumab), 19 May 2021; NICE TA1000 Final Appraisal Determination (iptacopan), 4 September 2024; NHS England HSS PNH commissioning and resource-use data, 2023. Devolved-nation positions (Scotland's SMC, Wales's AWMSG) are assessed against NICE's Technology Appraisal precedent separately, reflecting their distinct advisory and adoption mechanisms relative to NHS England's mandatory funding obligation.

  • NICE Technology Appraisal status for both drugs verified against the published TA698 and TA1000 Final Appraisal Determinations
  • NHS England HSS commissioning structure (15 designated centres) and switch-programme outcome (~95% of patients on ravulizumab) verified against NHS England HSS PNH commissioning data, 2023
  • Iptacopan cost-effectiveness position verified against the published TA1000 Final Appraisal Determination and standard TA QALY threshold documentation
  • Commercial arrangement status for both drugs verified against the published TA698 and TA1000 guidance
FAQ

Frequently asked questions

Deliverables
What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources
What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only — regulatory databases (FDA, MHRA, SFDA), peer-reviewed journals (NEJM, Blood, JAMA), live payer and HTA body publications (NICE, ICER, MOH), and NHS commissioning documentation. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation
Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.
Get Started

Commission this assessment

AXLRx PNH Payer & HTA is built for market access, HEOR, and pricing teams navigating NICE's standard Technology Appraisal route for both ravulizumab and iptacopan and NHS England HSS commissioning in the UK PNH market. Custom assessment in 72 hours.

1
Submit your request

Specify indication, payer focus (NICE HST/TA, NHS commissioning, PAS), and commercial question.

2
Scoping call

AXLRx analyst confirms payer scope, NICE classification analysis, and delivery format.

3
Delivery

Research-verified assessment in 72 hours with optional analyst readout.

Request Assessment View sample assessments